Evidence map›Paper›PMID 35933504›Full record

ArticleMolecular diagnosis & therapy2022

Epigenetics and ADHD: Reflections on Current Knowledge, Research Priorities and Translational Potential.

Charlotte A M Cecil, Joel T Nigg

Open access · hybridAbstract read
In one paragraph

Article in Molecular diagnosis & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
8.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The Role of Hydrogen Sulfide (HInternational journal of molecular sciences · 2023
    Pooled it
  4. Pooled it
  5. Effects of NR3C1 and COMT Genes on Attention-Deficit/Hyperactivity Disorder and Accompanying Aggressiveness: A Cross-Sectional Study in a Clinical Sample.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2026
    Article
  6. Review
  7. Review
  8. The Evolving ADHD Phenotype in the Externalizing Context.The American journal of psychiatry · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Phytoconstituents ofACS omega · 2025
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Charlotte A M CecilDepartment of Child and Adolescent Psychiatry/Psychology, Erasmus MC-Sophia, Rotterdam, The Netherlands. c.cecil@erasmusmc.nl.ORCID 0000-0002-2389-5922
Joel T NiggDivision of Psychology, Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA.
Leiden University Medical Center · NLOregon Health & Science University · US

Funding

ADHD heterogeneity, mechanisms, and risk profileR37MH059105 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI NIGG, JOEL T · 2014 to 2023
$7.0M
Developmental origins and early detection of ADHD and dysregulatory psychopathologyR01MH124824 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI SULLIVAN, ELINOR L. · 2021 to 2025
$3.8M
NIMH NIH HHS R01 MH124824NIMH NIH HHS R37 MH059105
6 · The paper itself

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a common and debilitating neurodevelopmental disorder influenced by both genetic and environmental factors, typically identified in the school-age years but hypothesized to have developmental origins beginning in utero. To improve current strategies for prediction, prevention and treatment, a central challenge is to delineate how, at a molecular level, genetic and environmental influences jointly shape ADHD risk, phenotypic presentation, and developmental course. Epigenetic processes that regulate gene expression, such as DNA methylation, have emerged as a promising molecular system in the search for both biomarkers and mechanisms to address this challenge. In this Current Opinion, we discuss the relevance of epigenetics (specifically DNA methylation) for ADHD research and clinical practice, starting with the current state of knowledge, what challenges we have yet to overcome, and what the future may hold in terms of methylation-based applications for personalized medicine in ADHD. We conclude that the field of epigenetics and ADHD is promising but is still in its infancy, and the potential for transformative translational applications remains a distant goal. Nevertheless, rapid methodological advances, together with the rise of collaborative science and increased availability of high-quality, longitudinal data make this a thriving research area that in future may contribute to the development of new tools for improved prediction, management, and treatment of ADHD.

Indexed as

Attention Deficit Disorder with HyperactivityDNA MethylationEpigenesis, GeneticEpigenomicsHumansResearch

Identifiers

PMID35933504
PMCPMC7613776
OpenAlexW4297778544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.